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Abstract
Background: Surgical resection is the standard treatment for liver metastases, although for the majority
of patients this is not possible. Stereotactic body radiotherapy (SBRT) is an alternative local-regional
therapy. The purpose of this study was to evaluate the results of SBRT for secondary liver tumours from
a combined multicentre database.
Methods: Variables from patients treated with SBRT from four Academic Medical Centres were entered
into a common database. Local tumour control and 1-year survival rates were calculated.
Results: In total, 153 patients (91 women) 59  8.4 years old with 363 metastatic liver lesions were
treated with SBRT. The underlying primary tumour arose from gastrointestinal (GI), retroperitoneal and
from extra-abdominal primaries in 56%, 8% and 36% of patients, respectively. Metastases, with a gross
tumour volume (GTV) of 138.5  126.8 cm3, were treated with a total radiation dose of 37.5  8.2 Gy in
5  3 fractions. The 1-year overall survival was 51% with an overall local control rate of 62% at a mean
follow-up of 25.2  5.9 months. A complete tumour response was observed in 32% of patients. Grade
3–5 adverse events were noted in 3% of patients.
Conclusion: Secondary liver tumours treated with SBRT had a high rate of local control with a low
incidence of adverse events.
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Introduction
Liver metastases are the most common hepatic tumour. More
than 40 000 patients with liver metastases from colorectal cancer
are diagnosed per year in the USA.1 Surgical resection is the stand-
ard of treatment for selected secondary liver tumours, but less
than 20% of patients are amenable to an operation due to
advanced local disease or a medical condition.2 Alternative local/
regional therapies have commonly been used for palliation or in
an attempt to cure.3 Radiofrequency ablation (RFA), trans-arterial
chemo-embolization (TACE) and Y90 embolization have encoun-
tered limitations mainly as a result of the tumour location, size,
number or underlying liver dysfunction.4–7
Stereotactic radiosurgery (SRS) was initially developed for
brain tumours with response rates above 60%.8 It allows for a
precise delivery of large doses of radiation to the tumour while
sparing the surrounding normal tissues.8,9 Further advances in
stereotactic body radiotherapy (SBRT) have overcome the diffi-
culties presented by the inherent movement of abdominal organs
that occurs during the respiratory cycle. Four broad categories of
respiratory control have been developed in order to deliver high
doses of radiation to liver tumours: tumour motion dampening,
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respiratory gating, active breathing coordination and tumour
tracking. The tracking of the tumour during the patients normal
respiratory cycle is performed by: (a) an internal fluoroscopic
monitoring of fiducial markers placed in or around the tumours;
(b) a computer software that creates an algorithm linking the
tumour movement with the chest wall movement; and (c) infra-
red Light Emitting Diodes (LED) placed on the patient’s chest and
a wall-mounted infra-red detector which allows for the construc-
tion of a patient’s breathing model. The accuracy of radiation
delivery during a standard treatment was 0.3 0.1 mm as meas-
ured at three different SBRT facilities.6 An initial experience with
17 patients whom underwent SBRT for liver tumours showed high
response rates with low adverse events.4 The aim of the present
study was to analyse the results of SBRT for secondary liver
tumours from four academic centres with the use of two different




Information from patients who underwent SBRT as treatment
for secondary liver tumours from four Academic Medical Centres
were merged into Institutional Review Board (IBR)-approved
databases for analysis. Patients treated from April 2000 to
September 2010 were entered. They were assessed by a multi-
disciplinary team formed with hepatobiliary surgeons, radiation
oncologists, medical oncologists and nurse practitioners. Inclu-
sion criteria included: (i) biopsy-proven metastatic liver malig-
nancy, (ii) non-resectable disease and (iii) a life expectancy of at
least 3 months. Limited information was available for patients
with ovarian, lung and genito-urinary (GU) liver metastases due
to a combination of a limited number of patients and low com-
pliance with follow-up.
A search of current published literature was performed by the
use of PubMed (http://www.ncbi.nlm.nih.gov/pubmed) where
the keywords metastatic liver, SBRT and cancer treatment were
entered into the webpage engine. From 1997 to 2011, 31 articles
were published. Articles were reviewed and the ones where data
were presented and reported in similar format as the present
report were considered in the final pooled analysis. Fourteen
studies were finally included for a total of 541 patients with a
similar distribution of liver metastatic malignancies when com-
pared with the current study population.3–5,10–20
Stereotactic body radiation therapy (SBRT)
Although protocols differed from one Institution to another, the
radiation plan for each patient at all Centers was developed,
reviewed and approved by a surgeon, a radiation oncologist, a
medical oncologist and a physicist. All patients were staged with
contrast-enhanced computerized tomography (CT scan), mag-
netic resonance imaging (MRI) and/or positron emission tomog-
raphy scan (PET). Regional lymph nodes were not included in the
treatment plan. Subsequent imaging for treatment plan develop-
ment and contouring was obtained as needed and according to
institution guidelines and payer approval. Three to six fiducial
markers were placed (3 to 5 mm in size) under different techniques:
percutaneously under CT guidance, using laparoscopic techniques
or at open surgery. Markers were inserted within or around the
tumour tissue and at a minimum distance of 2 cm between adja-
cent markers.7,8,10 One week was provided between markers place-
ment and imaging studies for SBRT treatment planning.
The treatment delivery technique varied by institution mainly
because of the type of equipment available: (i) two centres had
treatment delivered with the CyberKnife® system, providing
therapy in several fractions on consecutive weekdays. In brief,
subject’s imaging was imported into the Multiplan™ treatment
planning system version 2.05 (Accuray Inc., Sunnyvale, CA, USA)
and digitally fused in order to contour the gross tumour volume
(GTV). An additional margin of about 3–5 mm was added in
order to obtain the planning target volume (PTV). Patients were
immobilized for imaging using a custom Alpha Cradle (Smithers
Medical Products, Akron, OH, USA) and fitted with a synchrony
vest. 100 to 300 6 MV X-ray beams were used for each plan. SBRT
was performed under real-time kilovoltage camera fiducial track-
ing and real-time respiratory motion modelling using a separate
Synchrony® Respiratory Tracking System (Accuray Inc.). This
system is equipped with a robotic arm which can point the linear
accelerator from up to 1600 non-coplanar targeting angles. (ii)
The other two centres performed treatment on their patients
using the Novalis ExacTrac® patient positioning system (Brain-
LAB AG, Heimstetten, Germany). This consists of a vacuum
cushion bag for positioning and external body fiducial markers
monitor from two ceiling-mounted infrared cameras. Respiratory
gating was obtained using a relaxed, end-expiratory breath-hold
technique. Treatment planning was performed using the BrainS-
can® treatment planning system (BrainLAB). The GTV was con-
toured on CT scans fused with MRI and/or PET scans, when
available. The PTV was generated with an expansion of the GTV
of 10 mm in the craniocaudal direction and 7 mm in other direc-
tions. SBRT was delivered with the Novalis™ linear accelerator
system using conformal arcs or multiple fixed coplanar beams.
The average treatment time was 2 h per fraction.
Assessment of treatment response and
tumour recurrence
Follow-up of patients included a full physical examination, blood
work and imaging studies (CT, MRI and/or PET scans). They were
scheduled every 3 months for 2 years after SBRT. Patients who
survived >2 years were assessed every 3 to 6 months depending
upon clinical needs. The maximum tumour diameter and the
GTV were measured exporting the images to the SBRT planning
system (Multiplan or BrainLAB). Local control was defined as an
absence of radiological progression of the treated lesion. A
tumour response to SBRT was graded using RECIST 1.1 criteria
(Response Evaluation Criteria in Solid Tumors version 1.1).21,22
This system has four tumour response grades: a complete
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response (CR) or disappearance of all target lesions; a partial
response (PR) when at least a 30% decrease in the sum of the
longest diameter (LD) of target lesions was observed, taking as
reference the baseline sum of the LD; progressive disease (PD) was
granted when at least a 20% increase in the sum of the LD of target
lesions was noted, taking as reference the smallest sum LD
recorded since the treatment started or the appearance of one or
more new lesions; stable disease (SD): neither sufficient shrinkage
to qualify for PR nor a sufficient increase to qualify for PD, taking
as reference the smallest sum LD at the time treatment started.20 In
order to further evaluate partial tumour responses, a previously
published grading system was used based on tumour volume.4
Partial response grade I: at least a 10% decrease in tumour volume
but less than 30% from the original tumour volume; Partial
response grade II: a decrease in volume30% but <50% from the
original tumour volume; and Partial response grade III: a decrease
in tumour volume 50%. When there was no change in tumour
volume but vanishing of the enhancement or PET activity
resolved, it was scored as a grade III partial response.
Recurrences were also graded according to a previously pub-
lished scale.4 Grade 1: local recurrence (tumour progression
within or at the periphery of the radiation field manifested as
increased size or enhancement) with two subgroups, Grade 1a: 1
local recurrence and Grade 1b: > 1 local recurrences; Grade 2:
distant intra-abdominal recurrence (new tumour >3 cm away
from the radiation field or in another organ); Grade 3: distant
extra-abdominal recurrence; and Grade 4: a combination of local
and distant recurrences.
Adverse events
Adverse events after SBRT were graded on a 1–5 scale according to
National Cancer Institute Common Terminology Criteria for
Adverse Events (NCI CTCAE v3.0, http://www.cancer.gov).
Causes were attributed to surgery, the placement of fiducial
markers, chemotherapy or radiation therapy or related to medical
comorbidities.
Statistical analysis
A common database of clinical, imaging and SBRT variables for
each patient was created from four medical centres. Subjects and
tumour characteristics were expressed in mean standard devia-
tion. Parametric variables were compared by anova and when
differences were detected multiple comparisons between two
groups were performed using Student’s t-test. Non-parametric
variables, i.e. the occurrence of adverse events were compared
between groups using chi-square methods. A probability < 0.05
was defined as statistically significant using JMP Statistical Dis-
covery Software version 9.0 (SAS Institute, Cary, NC, USA).
Radiological evaluation of the tumour response was calculated at
3 months post-treatment follow-up and the 1-year overall survival
(OS) rate was calculated from the date of SBRT to the day of last
follow-up or death.
Results
The cohort of patients consisted of 153 patients (91 = 59%
female) with at a mean age of 59 8.4 years. A total of 363
tumours were treated. Patient demographics, characteristics of
their malignant condition and SBRT treatment parameters are
summarized in Table 1. The number of treated lesions per patient
was 2.5 1.1 with a gross tumour volume (GTV) of
138.5 126.8 cm3 and a mean follow-up of 25.2 5.9 months.
The 1-year overall survival was 51% whereas the overall local
control rate was 62%. Using RECIST criteria, 46 subjects had a
complete response (32%), 38 individuals had a partial response
(27%), 36 remained stable (26%) and 19 subjects (13%) showed
progression during follow-up (patients with ovarian malignancy
were not included). Ninety-two patients (60%) underwent
chemotherapy prior to SBRT treatment, 58 resections (38%), 34
RFA (22%) and 15 patients TACE (10%). The total radiation dose
delivered was 37.5 8.2 Gy in 5 3 consecutive fractions at an
isodose line of 70%. Grade 1 and Grade 2 adverse events from
SBRT were noted in 58 patients (38%) whereas Grade 3 & 4
toxicity was observed in five subjects (3%). No deaths were
recorded from SBRT treatment.
Eighty-five patients (56%) had metastases from the GI source.
The most common was from colorectal primary (n = 53 or 70%)
followed by pancreatic adenocarcinoma (n = 16 or 21%) and few
from other GI sources (GIST, n = 6 or 8%). There were no statis-
tical significant differences in the age or number of treated lesions
per patient when colorectal was compared with pancreatic
primary (P > 0.05, t-test, Table 1). Treated liver metastases from
colorectal cancer were significantly larger when compared with
liver metastases from pancreatic tumours [182 versus 60 cm3,
(means provided), respectively, P < 0.05, t-test]. In addition, the
method used to deliver a prescribed radiation dose to the tumour
(respiratory gating versus tumour tracking) had no effect on the
tumour response (P > 0.05, chi-square, Table 2). Recurrence pat-
terns of liver metastases were different. Patients with liver metas-
tases from a colorectal and pancreatic origin tend to have
recurrences both in field as well as distant from the treatment site.
The main pattern of recurrence for patients with liver metastases
from GIST was in the field. Local failures to SBRT (recurrence
Grade 1A) were noted mainly for liver metastases from adenocar-
cinoma of the pancreas (Table 1). Secondary liver tumours from
an abdominal primary other than the GI tract suffered small
numbers (Table 1). A complete or partial tumour response was
observed in 43 patients (65%) with other than GI-treated
tumours.
Overall adverse events were noted in 63 of the treated patients
(41%). No difference was noted in adverse events on patients
treated for colorectal metastases by the method used (respiratory
gating versus tumour tracking) even although the number of frac-
tions used to deliver the prescribed radiation dose was signifi-
cantly different (10 versus 3 fractions, P < 0.05 by t-test, Table 2).
Grade 1 adverse events, including fatigue and nausea, were
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observed in 55 subjects (36%) whereas Grade 2 and Grade 3
toxicities were recorded in 3 (1.9%) and 5 (3.2%) patients, respec-
tively (Table 3). No Grade 4/5 adverse events were noted.
Discussion
The present series report a multicentre experience with the use of
SBRT for non-resectable liver metastases from GI, non-GI and
extra-abdominal primaries. One hundred and fifty-three patients
with 363 metastatic liver lesions were treated with SBRT. There
were no differences in the tumour response for colorectal metas-
tases treated by SBRT using two different methods of radiation
delivery (respiratory gating versus tumour tracking). The 1-year
overall survival was 51% whereas the overall local control was
62% at a mean follow-up of 25.2 5.9 months with an overall
rate of Grade 2–3 adverse events of 5.1% and no Grade 4–5
toxicity.
To the best of the authors’ knowledge, the present study is the
largest experience with SBRT for liver metastases to date. It
showed SBRT as a safe technique for the precise delivery of
radiation to liver tumours minimizing parenchymal toxicity. It
supports further studies of SBRT as an alternative loco-regional
treatment modality for liver metastasis. Prospective trials, includ-
ing phase II and III studies, are in need to fully evaluate both the
Table 1 Demographics, baseline characteristics and response of tumours treated using stereotactic body radiation therapy (SBRT) from
patients with non-resectable liver disease from four Academic Medical Centres
From abdominal primary From retroperitoneal primary From extra-abdominal primary
Colorectal Pancreas Other GI Carcinoid Gen-urinary Sarcoma Breast Ovarian Lung
Number of patients 53 16 6 10 7 6 32 12 11
Age (years)
*mean (range) 66 (62–73) 64 (41–70) 59 (51–63) 48 (23–64) 64 (61–67) 59 (42–70) 56 (53–61) 70 (68–71) 65 (60–68)
Gender
Male/female 1.7:1 1:1 0.75:1 1.25:1 0.75:1 1.1:1 0.75:1 0.75:1 0.75:1
Lesions per patients 1.6 (1–6) 1.2 (1–3) 1.1 (1–3) 2.4 (1–3) 2.9 (1–3) 2.8 (2–3) 3.3 (1–5) 2.5 (1–4) 1.7 (1–4)
Median follow-up
(months)
17 14 33 11 92 21 13 21 19
One-year survival (%) 56 75 50 100 75 0 67 50 77
Overall local control
(%)




182 (60–581) 60 (22–476) 61 (38–215) 141 (8–301) 184 (41–326) 266 (42–340) 44 (10–85) 71 (32–116) 107 (63–206)
SBRT
Total dose (Gy) 41 36 27 39.2 43 31.3 38 30 46.5
RECIST, number (%)
CR 12 (23) 0 6 (100) 7 (70) 5 (71) 4 (66) 9 (29) NA 4 (40)
PR 20 (38) 4 (25) 0 0 0 1 (17) 11 (35) NA 2 (20)
SD 15 (28) 10 (62) 0 2 (20) 0 1 (17) 8 (25) NA 0
PD 6 (11) 2 (13) 0 1 (10) 2 (29) 0 4 (11) NA 4 (40)
Partial tumour response
Grade 1 10 (20) 3 (19) 0 NA NA NA NA NA NA
Grade 2 9 (16) 1 (6) 0 NA NA NA NA NA NA
Grade 3 1 (2) 0 0 NA NA NA NA NA NA
Tumour recurrence
Grade 1a 0 1 (6) 0 NA NA NA NA NA NA
Grade 1b 8 (15) 4 (25) 6 (100) NA NA NA NA NA NA
Grade 2 3 (6) 6 (40) 0 NA NA NA NA NA NA
Grade 3 5 (9) 0 0 NA NA NA NA NA NA
Grade 4 8 (15) 9 (56) 0 NA NA NA NA NA NA
GTV, gross tumour volume; NA, not applicable.
‘Other GI’ refers to other gastrointestinal tumours excluding colorectal, pancreatic and carcinoid tumours.
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role of SBRT as part of a multimodality primary approach and its
long-term efficacy.2 Patients with colorectal liver metastases ame-
nable to a resection have 5-year survival rates between 30% to
60%. Nevertheless, recurrences are frequent and in spite of
advances in chemotherapy the 5-year survival of patients with
recurrences is less than 5%.16,23–25 The current series and the pub-
lished data have shown a high local control rate for liver colorectal
metastases treated with SBRT20,26,27 even although treated lesions
in the present series were significantly larger (182 versus 44 cm3,
P < 0.05, t-test). In the present study, 53 patients with colorectal
liver metastases had a local control rate of 60% with a 1-year
survival rate of 56%. These results are concordant with a 42%
local control rate and 73% 1-year survival of 239 patients in the
literature3–6,10–12,15,16,20 (Table 4). The treatment of liver metastases
from pancreatic cancer is controversial. Patients tend to have a
tendency for systemic involvement and thus an overall poor prog-
nosis. Low numbers of patients in this group preclude further
meaningful analysis. While patients with liver metastases from
colorectal and pancreatic primaries tend to recur both in the field
and systemically, those with liver metastases from GIST had in
field recurrences. Local failures to SBRT (recurrence Grade 1A)
were noted mainly for adenocarcinoma of the pancreas. Recur-
rence patterns for specific tumours may help authors to develop
protocols that optimize long-term results after SBRT treatment.
Liver metastases develop in more than half of the patients with
stage IV breast cancer.29 Out of all the patients with metastases to
Table 2 Response of liver metastases from colorectal primary to stereotactic body radiation therapy (SBRT) using a radiation delivery
method to the tumour
Radiation delivery method P-value
RG TT
Number of patients 37 16
Characteristics of lesions
Number per patient (M  STDV) 1.7  1.4 1.5  0.8 NS
Tumour gross volume (cc) 217  181 183  172 NS
Total +partial response (%) 58 61 NS
Total radiation dose (Gy) 46  9 39  9 NS
Number of fractions 10  2 3  3 <0.05
Grade 3–5 adverse events (%) 0 0
RG, respiratory gating; TT, tumour tracking; NS, no significant.
Table 3 Adverse events reported in 153 patients with non-resectable secondary liver tumours treated by stereotactic body radiation therapy
(SBRT) (A) from four Academic Centres and (B) from the published literature
(A) Academic Centres
(n = 153)
Grade 1 Grade 2 Grade 3 Grade 4 Grade 5
Primary tumour, n (%)
Colorectal 32 (21) 0 0 0 0
Pancreas 8 (5.2) 0 0 0 0
Other GI 1 (0.06) 2 (1.3) 0 0 0
Carcinoid 5 (3.2) 0 5 (3.2) 0 0
Breast 9 (5.8) 1 (0.06) 0 0 0
Sarcoma 0 0 0 0 0
Total (%) 55 (36) 3 (1.9) 5 (3.2) 0 0
(B) Published literature
(n = 541)
Grade 1 Grade 2 Grade 3 Grade 4 Grade 5
Primary tumour (%)
Colorectal 21 9 6 0.2 0
Pancreas 68 27 0 0 0
Other GI 29 2 3 0 0
Carcinoid 27 9 0 0 0
Breast 26 15 6 0.9 1.3
Total as mean (%) 34 12 3 0.22 0.3
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the liver, 5% will have isolated liver involvement. Even with sys-
temic chemotherapy, the median survival for those patients with
liver exclusive or limited extra-hepatic disease is 19 to 26
months.29 Hormonal therapy is of limited use because breast
tumours that metastasize to the liver typically are hormone recep-
tor negative.29 After a resection, if feasible, the median survival is
27 to 57 months.30 SBRT has also been used as treatment modality
for breast metastases to the liver.31 In the present review of the
literature, 62 patients were identified as having been treated with
SBRT with a 1-year survival rate of 64%3–5,10–12,15,16,26 (Table 4).
Within the current series, treated patients with breast liver metas-
tases (n = 32) had a 1-year survival rate of 67% and a local tumour
control rate of 62%. Other secondary liver tumours such as GU
tumours had a significantly lower tumour response to SBRT when
compared with the published series5,10–12 (38% versus 81%,
P < 0.05, t-test). This discrepancy may be as a result of a longer
follow-up in the current series (92 versus 9.6 months, means
provided, respectively) and larger GTV’s (184 versus 23 cm3,
means provided, respectively) at a similar delivered radiation
dose. The 1-year survival rate of patients with liver metastases
from sarcoma was null in this study and 61% in the literature3,10–16
(Table 4). This difference in tumour response may be explained by
a more advanced stage of the disease as manifested by larger
GTV’s in the patients from the present series (266 versus 23 cm3,
means provided, respectively).
Overall adverse events were noted in 41% (n = 58) of treated
patients (Table 3). Most of the recorded adverse events in the
present study were Grade 1 including nausea and transient
fatigue, rates comparable with the rates observed by others
(Table 3). Grade 4 and 5 toxicities were rare and reported in <1%
in the present series and the reported literature.3–5,10–20 One death
was observed from liver failure 7 weeks after SBRT in a patient
who received greater than 10 Gy to 60% of his liver.28 Another
patient was found to have liver fibrosis, portal hypertension and
bleeding from oesophageal varices after treatment with SBRT of
two liver metastases close to the liver hilum.12
The presented descriptive series should be interpreted in the light
of its relative small numbers. Patients were managed in a multidis-
ciplinary and multi-modality approach under IRB-approved pro-
tocols. The present study describes the largest series of patients with
metastatic liver tumours treated with SBRT, in whom 1-year sur-
vival was 51% with low toxicity. Future studies are required to better
define the role of SBRT for the treatment of liver metastases.
Conflicts of interest
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Table 4 Demographics, baseline characteristics and response of tumours treated by stereotactic body radiation therapy (SBRT) from
patients with non-resectable liver disease from the published literature
From abdominal primary From retroperitoneal primary From extra-abdominal primary
Colorectal Pancreas Other GI Carcinoid Gen-urinary Sarcoma Breast Ovarian Lung
Number of patients 239 21 9 20 11 130 62 13 36
Age (years)
Mean (range) 61 (55–72) 58 (55–60) 61 (55–70) 60 (60–65) 55 (60–65) 60 (55–60) 58 (55–60) 58 (55–64) 57 (55–60)
Gender
Male/female 1.4:1 0.9:1 1:1 0.75:1 NR 1.1:1 0.75:1 0.75:1 0.75:1
Lesions per patients 1.5 NR NR 1.5 NR NR 3.3 NR NR
Median follow-up
(months)
16 12 14 14 10 16 14 12 14
One-year survival (%) 73 69 61 77 74 61 64 73.3 81
Overall local control
(%)




44 (10–252) 23 (10–386) 23 (10–229) 37 (22–46) 23 (10–46) 23 (10–229) 20 (10–386) 37 (18–386) 23 (10–386)
SBRT
Total dose (Gy) 40 32 39 34.4 32.3 39.3 36.3 35.7 37.4
RECIST (%)
CR 50 (21) 4 (18) 3 (35) 6 (33) 4 (36) 46 (35) NR NR NR
PR 100 (42) 5 (25) 4 (44) 9 (45) 4 (36) 52 (40) NR NR NR
SD 45 (19) 4 (18) 1 (11) 0 3 (27) 8 (6) NR NR NR
PD 41 (17) 0 1 (11) 4 (22) 0 24 (18) NR NR NR
GTV, gross tumour volume; NR, not reported.
‘Other GI’ refers to other gastrointestinal tumours excluding colorectal, pancreatic and carcinoid tumours.
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